How much revenue from Glybera? What is the price of Glybera. How much revenue from ARWR or ACAD? You have cornered the biotech world like the Hunt Brothers did with silver. t
So you really aren't a separate entity but rather part of the ID machine of darkness. You as a robot are giving me too much credit. I only relay discovery information of what has transpired in developments with the technology. I have no effect on share price. A coincidence that you popped back up because IONS had good data yesterday......Can I call you Rosey like on the Jetson's? t
Being jealous of other people will not really help you in the long run sky king. t
RGLS was helped by IONS. Dr. Crooke was and is a willing helper....but he was smart enough to not bet the farm on this very new technology. IONS made a goodly sum of money for their investment. They are separate companies. Any one of these over 40 ID's controlled by you know who should really have some humility and realize that even RGLS has more potential than vicl. t
BTW Glybera is an overpriced gene therapy that doesn't hold over time....it gets divided out from the liver cells. This area could be shark ground for IONS ApoCIII inhibitor in lowering triglycerides and helping prevent recurrent and chronic pancreatitis. t
A real injustice....god and a judge on the same message board. BTW, Chipotle is giving away free burritos....thought you'd like to know. Soon I'll break down the pipeline of XENE for you as a return favor for all of your help. t
Oral delivery was possible when he said that, just not feasible. With drugs coming out soon you will have 5 X 10 X 30= 1500 times more potent. How did I get that number? The 2.0+ generation drugs are 5 times more potent than the plain 2.0 generation drugs. The 2.5 generation drugs are another 10 times more potent than the 2.0+ drugs, and with the LICA system for delivery you increase that potency by another 30 fold. When you bring up Santaris you might really want to look into what you are saying. They were bought out about three years ago by Roche. This arguably the biggest big pharma in the world and yet there is nothing to show for that as they have a double whammy over there at Santaris. They do cross into some of IONS patents, and they also have increased toxicity with the of LNA's. t
I bet a lot of Brits would love to have had their money in RNN vs. a Barclays right now:)) t
Review of case reports uncovers rheumatologic disease in 13 patients taking checkpoint inhibitors.
Case reports on 13 cancer patients suggest that a small number of cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at some higher?than?normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns Hopkins Medicine researchers. ?I don't think anyone is particularly surprised that rheumatologic disorders might be a complication of drugs that boost the immune system,? says study author Laura C. Cappelli, M.D., a rheumatologist at the Johns Hopkins University School of Medicine. But the new study, however small in sample size, she says, is believed to be the largest published case series of a link between the drugs and the diseases. The patients described in the new case report make up only about 1.3 percent of the total patients treated with drugs ? singly or in combination ? at The Johns Hopkins Hospital from 2012 to 2016, Cappelli says, but if further research confirms a cause?and?effect relationship, the rate is likely an underestimation of how common rheumatologic diseases are in patients taking so?called immune checkpoint inhibitors. She notes that patients with only mild joint pain, for instance, or those with already deteriorating health from their cancers may not have been referred to the rheumatology clinic for their symptoms. Between 2012 and 2016, 13 patients at the Johns Hopkins Kimmel Cancer Center who were taking one or both drugs to treat their cancers developed new?onset arthritis or sicca syndrome, a set of autoimmune conditions causing dry eyes and mouth, including Sjogren?s syndrome. The cases were described online June 15 in Annals of the Rheumatic Diseases.
It is nice to know that you are God and passing judgment on me. You might however want to look into the mirror and really really "reflect" on your own disservice with people telling them to buy vicl at four bucks and now we are four bucks again after a ten:one stock split. Thank you god. t
You need to short IONS so that you can use all of those profits to buy more of your high quality stocks. Hope you don't have anyone in the family that will have to use the one drug from ACAD that will cost over $2000 per month....which is actually more that the PCSK 9 inhibitors cost. But you've got connections just like your inside info on Cramer so it would probably only cost you a burrito. t
When you say the "word is" that is again where you lose credibility. "Word is" what's your source? A little proof would be nice instead of more conjecture. One burrito to tempt you to go to the annual meeting and maybe somethings being talked about might have sunk in....or again, maybe not. t
Volanesorsen is an antisense drug in development intended to treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowering agents. Volanesorsen is designed to reduce the production of ApoC-III, a protein produced in the liver that plays a central role in the regulation of plasma triglycerides.
Results from the study showed that, in addition to reductions in plasma TG and apolipoprotein C-III (ApoC-III), a key factor in TG regulation, volanesorsen improved insulin sensitivity and glucose control. Volanesorsen is currently being evaluated in two pivotal Phase 3 studies—the APPROACH FCS study in patients with familial chylomicronemia syndrome and the Broaden FPL study in patients with familial partial lipodystrophy. In addition, the Compass study—a Phase 3 study designed to support global regulatory filings—is also ongoing.
In patients treated with volanesorsen, ApoC-III and TG levels decreased on average 88% and 69%, respectively, compared to baseline, and HDL-cholesterol increased an average of 42%. In addition, insulin sensitivity increased an average of 50% and correlated well with reductions in both plasma ApoC-III
In addition, improvements in markers of glycemic control were observed, including statistically significant decreases in glycated albumin and fructosamine after three months of dosing, and a decrease of 0.44 percentage points in HbA1C observed three months post-dosing.
The majority of adverse events reported in both groups in the study were mild in severity with no discontinuations from the study due to adverse events. There were no clinically relevant changes in blood serum chemistries, hematology, urinalysis, inflammatory markers, electrocardiogram, or vital signs.
Also, a biotech company going after acne?!?! Is that really the best use of resources? And with everything out there now for that indication, including a ton of OTC meds, prescription pills and creams, laser therapies, and things like silk peels I really don't think they are going to be cost competitive with that endeavor. t
A buyout might save ACAD....but if that was my criteria for owning a stock I'd rather take my chances with MDVN. t
Keep watching ACAD too. An approved drug just lately and the share price is actually much lower. The drug is priced too high, the dedicated followers are dreaming about expanded indications, and the pent-up demand may not be as high as Wall Street led you to believe. As far as ARWR is concerned they are going after one of the three most competitive areas in biotech....Hep B. Instead of thinking catalytics you might want to be thinking cash.....and lots of it as that will be needed to accomplish their goal. t